Amplia

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Science

Contact

Board

Company Overview

Team

Corporate Governance

Corporate Directory

Values

Clinical Advisers

About Us

Video Updates

Presentations

In the News

Communication

Updates

US Shareholders

Investor FAQs

Shareholder Services

Research Reports

Reports

Announcements

Investor Fact Sheet

Top 20 Shareholders

Share Price

Investor Centre

Clinical Trial

Webinars

Home

Montserrat

Amplia Therapeutics Limited

Amplia has announced the granting of a key patent in Europe and Japan. The patent, entitled A salt and crystal form of a FAK Inhibitor, describes the specific chemical form of the company’s best-in-class FAK inhibitor narmafotinib.

The Company has received notification from the Japanese Patent Office that the patent was granted in Japan on 18 July 2024, whilst the European Patent Office have advised that the patent will grant in Europe on 28 August 2024.

Amplia’s CEO and Managing Director Dr Chris Burns comments:

“The granting of this patent by two of the world’s most respected patent offices bodes well for granting of the patent in other jurisdictions, including the US and Australia. Importantly from a commercial perspective, this patent extends protection for narmafotinib out to at least 2040.”

Click link below to read the full ASX Release.

Key chemical form patents in Europe and Japan